Zealand Pharma shares are expected to surge when markets open on Tuesday after Boehringer Ingelheim released striking Phase III data showing survodutide, the GLP-1/glucagon dual agonist co-developed with the Danish biotech, delivered a 34% reduction in visceral fat and a 63% reduction in liver fat among people living with obesity. The figures, disclosed on Monday, immediately drew comparisons to the most successful obesity drugs on the market, reigniting debate about whether Zealand Pharma remains a standalone company or represents an attractive acquisition target for a major pharmaceutical player.

Analysts at several European and US investment banks are expected to publish upgraded price targets for Zealand Pharma on Tuesday morning, citing the visceral fat data as a clinically meaningful differentiator. Visceral fat reduction is increasingly regarded by endocrinologists as a more important metabolic endpoint than total body weight loss, and a 34% reduction would place survodutide ahead of or competitive with current approved therapies in that specific measure. The liver fat figure of 63% is particularly notable for its implications in metabolic dysfunction-associated steatohepatitis, a large and underserved patient population.

The results strengthen Boehringer Ingelheim's position in the obesity and cardiometabolic space, where it has been aggressively investing to challenge Novo Nordisk and Eli Lilly. For Zealand Pharma, which retains co-commercialisation rights in certain geographies, the data validates years of pipeline investment and puts the company squarely in the sights of large-cap pharma groups looking to build out obesity franchises ahead of anticipated patent cliffs elsewhere. Pfizer, AstraZeneca, and Roche have each been named in analyst notes over the past twelve months as potential acquirers of obesity-focused biotechs.

Zealand Pharma's chief executive Adam Steensberg is expected to host a call with investors and analysts on Tuesday to discuss the data and outline next steps toward regulatory submission. The company is anticipated to signal an intention to file with the European Medicines Agency and the US Food and Drug Administration before the end of 2026, subject to finalisation of the complete Phase III dataset. Market participants will be watching for any commentary on partnership economics and milestone payment timelines, which could further catalyse the stock.

The survodutide data also arrives at a moment of heightened investor attention to the obesity drug space following recent readouts from competing programmes. With the global anti-obesity medication market projected to exceed $100 billion annually by the end of the decade, even incremental clinical differentiation carries substantial commercial weight. Zealand Pharma's Copenhagen-listed shares closed at a multi-month high on Friday and options markets had already begun pricing in elevated volatility ahead of Tuesday's anticipated analyst commentary.